Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients.
作者信息
Cohen Alexander T
机构信息
Department of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, Westminster Bridge Road, London, UK.
出版信息
Eur Heart J Suppl. 2018 May;20(Suppl E):E1-E2. doi: 10.1093/eurheartj/suy014. Epub 2018 May 9.
Abstract
摘要
相似文献
1
Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients.使用贝曲西班进行延长血栓预防：急性内科疾病患者的新标准。
Eur Heart J Suppl. 2018 May;20(Suppl E):E1-E2. doi: 10.1093/eurheartj/suy014. Epub 2018 May 9.
2
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).延长疗程贝曲西班相对于住院内科患者标准剂量依诺肝素降低卒中风险：APEXX 试验亚组研究（急性内科疾病静脉血栓栓塞预防用延长疗程贝曲西班）。
Circulation. 2017 Feb 14;135(7):648-655. doi: 10.1161/CIRCULATIONAHA.116.025427. Epub 2016 Nov 14.
3
Pharmacological properties of betrixaban.贝曲西班的药理特性。
Eur Heart J Suppl. 2018 May;20(Suppl E):E12-E15. doi: 10.1093/eurheartj/suy016. Epub 2018 May 9.
4
Betrixaban for prevention of venous thromboembolism in acute medically ill patients.贝曲西班用于预防急性内科疾病患者的静脉血栓栓塞
Eur Heart J Suppl. 2018 May;20(Suppl E):E16-E22. doi: 10.1093/eurheartj/suy017. Epub 2018 May 9.
5
Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.贝曲西班用于预防伴有静脉血栓栓塞危险因素的急性内科疾病患者的一线静脉血栓栓塞。
Expert Rev Cardiovasc Ther. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15.
6
New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.内科疾病患者延长血栓预防的新范式
J Clin Med. 2020 Apr 2;9(4):1002. doi: 10.3390/jcm9041002.
7
Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment.直接口服抗凝剂用于内科疾病患者的延长血栓预防：荟萃分析与风险/效益评估
J Blood Med. 2018 Feb 21;9:25-34. doi: 10.2147/JBM.S149202. eCollection 2018.
8
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.贝曲西班：一种新型口服 Xa 因子抑制剂，用于高危住院患者的延长静脉血栓栓塞症预防。
Ann Pharmacother. 2018 Jun;52(6):554-561. doi: 10.1177/1060028018754383. Epub 2018 Jan 17.
9
Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.贝曲西班延长预防疗法对比标准时长预防干预对急性内科疾病患者静脉血栓栓塞症的有效性和安全性：系统文献回顾和网络荟萃分析。
J Med Econ. 2019 Oct;22(10):1063-1072. doi: 10.1080/13696998.2019.1645679. Epub 2019 Aug 9.
10
Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis.通过延长预防血栓形成的时间来减轻急性内科疾病患者静脉血栓栓塞的负担。
Eur Heart J Suppl. 2018 May;20(Suppl E):E6-E11. doi: 10.1093/eurheartj/suy015. Epub 2018 May 9.
引用本文的文献
1
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.预防还是不预防，以及预防多少和多久？包括 COVID-19 住院患者在内的内科住院患者静脉血栓栓塞症预防的争议。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):506-514. doi: 10.1182/hematology.2022000403.
2
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.利伐沙班用于医疗疾病住院后延长血栓预防的获益-风险评估。
J Am Heart Assoc. 2022 Oct 18;11(20):e026229. doi: 10.1161/JAHA.122.026229. Epub 2022 Oct 7.
3
New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients.内科疾病患者延长血栓预防的新范式
J Clin Med. 2020 Apr 2;9(4):1002. doi: 10.3390/jcm9041002.
4
Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.贝曲西班用于高危住院患者的静脉血栓栓塞症延伸预防：将 APEX 结果付诸实践。
Drugs. 2019 Feb;79(3):291-302. doi: 10.1007/s40265-019-1059-y.
本文引用的文献
1
Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US.一种近乎普遍的基于住院治疗的预防方案对美国每年静脉血栓栓塞事件数量的影响。
Blood. 2017 Jul 13;130(2):109-114. doi: 10.1182/blood-2016-12-758995. Epub 2017 May 8.
2
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).延长疗程贝曲西班相对于住院内科患者标准剂量依诺肝素降低卒中风险：APEXX 试验亚组研究（急性内科疾病静脉血栓栓塞预防用延长疗程贝曲西班）。
Circulation. 2017 Feb 14;135(7):648-655. doi: 10.1161/CIRCULATIONAHA.116.025427. Epub 2016 Nov 14.
3
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.急性病医学患者贝曲西班的延长血栓预防。
N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27.
4
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.贝曲西班简介及其在预防和治疗静脉血栓栓塞中的潜力。
Vasc Health Risk Manag. 2015 Jun 26;11:343-51. doi: 10.2147/VHRM.S63060. eCollection 2015.
5
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.急性重病静脉血栓栓塞症预防的贝曲西班延长疗程设计和原理（APEX）研究。
Am Heart J. 2014 Mar;167(3):335-41. doi: 10.1016/j.ahj.2013.11.006. Epub 2013 Dec 10.
6
Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism.心脏病患者专页。美国卫生局局长预防深静脉血栓形成和肺栓塞的行动呼吁。
Circulation. 2009 Apr 21;119(15):e480-2. doi: 10.1161/CIRCULATIONAHA.108.841403.
7
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.欧洲的静脉血栓栓塞症（VTE）。VTE事件的数量以及相关的发病率和死亡率。
Thromb Haemost. 2007 Oct;98(4):756-64. doi: 10.1160/TH07-03-0212.
Zotero 插件